Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04413123 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
A Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma, sponsored by Bradley A. McGregor, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT04413123 is a Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma that is active but no longer recruiting, run by Bradley A. McGregor, MD. The registered enrollment target is 60 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT04413123, a Phase 2 study of Renal Cell Carcinoma and Chromophobe Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Bradley A. McGregor, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Cabozantinib
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Brigham & Woman's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Texas
- UT Southwestern Medical - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2026-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04413123
The ClinicalTrials.gov registry entry for NCT04413123 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Bradley A. McGregor, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04413123 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT04413123 about?
NCT04413123 is a clinical study titled "Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC". This research study will assess whether cabozantinib, nivolumab and ipilimumab in combination are safe and effective in slowing down the growth of kidney cancer(renal cell carcinoma or RCC) that has advanced or spread to other areas the body.
What is the current status of trial NCT04413123?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-11-05. Estimated completion is 2026-12-20.
What conditions does trial NCT04413123 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma.
What interventions are being tested in trial NCT04413123?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT04413123?
This trial is sponsored by Bradley A. McGregor, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04413123 being conducted?
This trial has 4 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
RECRUITING · Phase 2
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)
RECRUITING · Phase 2
-
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
-
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 2
Explore more on PlainTrial
Renal Cell Carcinoma
All registered trials for this condition
Chromophobe Renal Cell Carcinoma
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.